HSV Based Virotherapy Market Analysis

  • Report ID: 3115
  • Published Date: Dec 24, 2024
  • Report Format: PDF, PPT

Herpes Simplex Virus Treatment Segmentation

The global Herpes simplex virus treatment market is segmented by type into anti-cancer oncolytic viruses, viral vectors gene therapy and viral immunotherapy, out of which, the anti-cancer oncolytic viruses segment is anticipated to hold the largest share in the market during the forecast period on account of growing investment in developing treatment methods for cancer backed by mounting cases of cancer. As per other report by the WHO, in 2020, Lung cancer was the cause of 1.80 million deaths, whereas 935 000 deaths were caused by colon and rectum cancer; liver cancer was responsible for 830 000 deaths of the total deaths and breast cancer caused 685000 deaths. Furthermore, increasing government funding to increases cancer screeningand curb the cases of cancer mortality, is estimated to boost the market growth. On the basis of end-user, the market is segmented into hospital, research center, specialty clinics, and others. Out of these, the research center segment is estimated to garner the major share over the forecast period owing to the ongoing clinical research on virotherapy with HSV.

Our in-depth analysis of the global market includes the following segments:

 

By Type

  • Anti-Cancer Oncolytic Viruses
  • Viral Vectors Gene Therapy
  • Viral Immunotherapy

 

By Application

  • Cancer
  • Genetic Diseases
  • Others

By End-User

 

  • Hospital
  • Research Centers
  • Specialty Clinics
  • Others

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of herpes simplex virus treatment is assessed at USD 3.03 billion.

Herpes Simplex Virus Treatment Market size was valued at USD 2.84 billion in 2024 and is expected to reach USD 7.45 billion by 2037, expanding at around 7.7% CAGR during the forecast period i.e., between 2025-2037.

North America industry is predicted to account for largest revenue share by 2037, on the back of high government investment in this sector, along with presence of leading pharmaceutical companies conducting innovative clinical experiments.

The major players in the market are Sorrento Therapeutics, Inc., Replimune Group Inc., Shanghai Sunway Biotech Co., Ltd, Merck & Co, Inc., Amgen Inc., Oncolytics Biotech Inc., Transgene SA, PSIOXUS Therapeutics Limited and others.
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos